Drug Trial Radar · NCT01533220
Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal
Last checked: Nov 19, 2026Latest source record: Jan 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Jan 1, 2013
Primary completion
Aug 31, 2013
Study completion Apr 30, 2014
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The common cold is a major cause of nasal obstruction and reaches children and adults two or more times a year. At the moment, there is no cure for the common cold, and therefore the reduction of symptoms is the focus of the treatment. The study has parallel distribution design, with two equal groups, in which one group will be treated by a combination of naphazoline hydrocloride + pheniramine maleate + panthenol and the other will receive treatment with naphazoline hydrocloride.
Conditions
- Flu
- Cold
- Allergic Disorder of Respiratory System
Interventions
naphazoline hydroclorideDrug
02 drops into each nostril, 04 times a day for 03 days
Naphazoline hydrocloride + Pheniramine Maleate + PanthenolDrug
02 drops into each nostril each 12 hours for 03 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of treatment in nasal congestion reduction based on Peak Flow Nasal Inspiratory (PFNI) assayTime frame: 3 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.